Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 110Carcinoma, Non-Small-Cell Lung 63Lung Neoplasms 27Hodgkin Disease 14Lymphoma 10Neoplasm Metastasis 9Triple Negative Breast Neoplasms 8Neoplasms 8Recurrence 7Prostatic Neoplasms 7Small Cell Lung Carcinoma 5Sarcoma 5Rhabdomyosarcoma 5Lymphoma, Large B-Cell, Diffuse 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Breast Neoplasms, Male 4Brain Neoplasms 4Adenocarcinoma of Lung 4Ovarian Neoplasms 3NSCLC 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Esophageal Squamous Cell Carcinoma 3

Interventions

Vinorelbine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pathologic Residual Cancer Cells × Vinorelbine × Clear all
NCT03703427 2018-10-12

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Shandong Cancer Hospital and Institute

Phase 2 Unknown
200 enrolled

Pathologic Residual Cancer Cells

Data powered by HemOnc (CC BY 4.0) Colophon âš¡